Physician profile
James Mark Harrison
NPI 1326042987
$3,050.34
in general payments reported to CMS, 2019-2025
20 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $564 · 2021: $308 · 2022: $257 · 2023: $338 · 2024: $430 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,377 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,376.93 |
| Education | $132.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $826.31 | 2019-2025 | |
| Optinose US, INC. | $496.06 | 2019-2025 | |
| Genzyme Corporation | $375.48 | 2019-2025 | |
| Medtronic, INC. | $333.64 | 2023-2025 | Stealthstation S8 Platform, Propel, Novapak |
| Regeneron Healthcare Solutions, INC. | $238.06 | 2020-2025 | Dupixent |
| Stryker Corporation | $135.55 | 2025 | Alphavent, Omega |
| Novartis Pharmaceuticals Corporation | $109.76 | 2019-2020 | |
| Novo Nordisk INC | $103.70 | 2022-2024 | Rybelsus, Ozempic |
| Acclarent, INC | $78.09 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $52.03 | 2025 | Neffy |
| Sight Sciences, INC. | $47.30 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Phathom Pharmaceuticals, INC. | $47.20 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $37.46 | 2021-2023 | |
| Amgen INC. | $34.00 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.02 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.13 | 2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $21.79 | 2025 | Tezspire |
| Eyevance Pharmaceuticals LLC | $21.47 | 2021 | |
| Abbvie INC. | $21.27 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.